Regulatory statusNo general FDA approval identified
What you need to know in 20 seconds
What is it?
Reproductive neuropeptide
Research focus
Reproductive endocrinology, fertility, psychosexual research
Human evidence
Controlled human studies demonstrate reproductive-hormone effects, oocyte-maturation triggering in specialist IVF settings, and acute sexual/emotional brain-processing effects in small randomized HSDD studies in men and women. Long-term HSDD efficacy is not established.
Regulatory status
No general FDA-approved kisspeptin therapy identified.
Main limitations
Routine fertility/sexual-function efficacy and long-term safety outside trials are not established.
Safety
Acute research exposure appears tolerable in small studies, but therapeutic long-term safety is not established; FDA highlights limited safety information for compounded kisspeptin-10.
i
Controlled human studies demonstrate reproductive-hormone effects, oocyte-maturation triggering in specialist IVF settings, and acute sexual/emotional brain-processing effects in small randomized HSDD studies in men and women. Long-term HSDD efficacy is not established.
What the evidence actually supports
✓Promising human mechanism research, not yet equivalent to an established HSDD treatment.
✓Useful mechanistic evidence, but not proof of durable therapeutic benefit.
✓This is legitimate human clinical evidence, but it belongs to reproductive medicine rather than lifestyle self-use.
What is not established / key limitations
×No long-term treatment efficacy, symptom-remission or routine dosing outcome established.
×No long-term clinical benefit or routine treatment regimen established.
×Does not establish safe unsupervised fertility use or libido enhancement.
Selected study & evidence records
Kisspeptin administration in men with hypoactive sexual desire disorder
2023 · Randomized double-blind placebo-controlled crossover study · n=37
Kisspeptin altered sexual/emotional brain processing and increased penile tumescence in experimental conditions.
Acute research exposure appears tolerable in small studies, but therapeutic long-term safety is not established; FDA highlights limited safety information for compounded kisspeptin-10.
Short experimental studies report generally acceptable acute tolerability, but long-term safety for repeated lifestyle use is not established. Fertility use requires specialist monitoring because of potent reproductive-axis effects.
Route / formulation boundaryEvidence differs between kisspeptin-10 and kisspeptin-54 and between IV and other routes.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusVerified dosing evidence added. Published human reproductive-study regimen; Published IVF trigger research regimen. See dosing_evidence records for route, regimen, population, duration and source.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
